KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Current Leases: 2021-2024

Historic Current Leases for Castle Biosciences (CSTL) over the last 4 years, with Dec 2024 value amounting to $1.7 million.

  • Castle Biosciences' Current Leases fell 16.96% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 16.96%. This contributed to the annual value of $1.7 million for FY2024, which is 46.44% up from last year.
  • Per Castle Biosciences' latest filing, its Current Leases stood at $1.7 million for FY2024, which was up 46.44% from $1.1 million recorded in FY2023.
  • Over the past 5 years, Castle Biosciences' Current Leases peaked at $1.8 million during FY2022, and registered a low of $1.1 million during FY2023.
  • Moreover, its 3-year median value for Current Leases was $1.7 million (2024), whereas its average is $1.5 million.
  • Its Current Leases has fluctuated over the past 5 years, first surged by 50.72% in 2022, then plummeted by 36.02% in 2023.
  • Over the past 4 years, Castle Biosciences' Current Leases (Yearly) stood at $1.2 million in 2021, then spiked by 50.72% to $1.8 million in 2022, then plummeted by 36.02% to $1.1 million in 2023, then surged by 46.44% to $1.7 million in 2024.